Theravance Biopharma Investigational Site
Cypress, California, 90630, United States
NCT Number: NCT03750565
A Phase 1, double blind, placebo controlled, 4 cohort, multiple dose study in healthy adult Japanese and Caucasian subjects.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Cypress, California, 90630, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For All subjects:
For Japanese subjects only:
For Caucasian subjects only:
Exclusion criteria
For all subjects:
oral capsule/tablet, QD
oral capsule/tablet, QD
oral capsule/tablet, QD
oral capsule/tablet, QD
Time frame: Day 1 & Day 14
Time frame: Day 1 & Day 14
Time frame: Day 1 & Day 14
Time frame: Day 1 & Day 14
Time frame: Day 1 & Day 14
Theravance Biopharma
Industry
A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Adult Japanese Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06023667
Colitis, Colitis, Ulcerative
Cincinnati, Ohio, United States
View Trial DetailsNCT04151420
Colitis, Colitis, Ulcerative
Maastricht, Netherlands
View Trial DetailsNCT06146816
Crohn Disease, Digestive System Diseases
Tel Aviv, Israel
View Trial DetailsNCT04757181
Digestive System Diseases, Gastroenteritis
Worcester, Massachusetts, United States
View Trial Details